

Human CD30 Monoclonal Antibody

Catalog No.: YR0005

Basic Information

Molecular Weight

150 kDa

Endotoxin

<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay

Sterility

0.2 μm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Brentuximab is a biosimilar directed against the extracellular domain of CD30. The brentuximab antibody selectively targets tumor cells expressing the cell membrane protein CD30 and delivers the MMAE, which causes apoptosis by preventing cell cycle progression of the G2 to M phase through disruption of the cytosolic microtubule network, thereby preventing tumor growth and proliferation.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Brentuximab Biosimilar

Isotype

Human IgG1 kappa

Immunogen

Recommended Isotype Control(s)

Recommended Dilution Buffer

1×PBS pH 7.0

Contact

☎ | 400-999-6126

✉ | cn.market@abclonal.com.cn

🌐 | www.abclonal.com.cn

Product Information

Production

Purified from cell culture supernatant in an animal-free facility

Purification

Protein A or G purification

Storage

2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)